Isocitrate dehydrogenase is a critical metabolic enzyme that catalyzes the conversion of isocitrate to α-KG in the tricarboxylic acid cycle. IDH occurs in three isoforms: IDH1, IDH2 and IDH3. 1 Mutations in IDH1 and IDH2 have been found in a variety of human cancers, including AML, malignant gliomas, intrahepatic cholangiocarcinoma, chondrosarcoma, and thyroid carcinomas. 2-4 IDH mutants gain neomorphic activity, which catalyzes the conversion of α-KG to 2-HG, resulting in an intracellular concentration of 2-HG that is over 100-fold higher in mIDH cells than in wild-type cells. 5-7 2-HG is a competitive inhibitor of multiple α-KG-dependent dioxygenases, including JmjC domain-containing
histone demethylases, 8, 9 tet methylcytosine dioxygenase 2 (TET2) and 5-methylcytosine hydroxylases, 9, 10 thereby linking metabolism to epigenetics and subsequent blockade of cell differentiation. [9] [10] [11] Several studies have suggested that IDH mutations play a key role in driving leukemogenesis and potentially solid cancers. [12] [13] [14] These findings have stimulated interest in the development of inhibitors of mIDH as anticancer agents. The mIDH2 inhibitor AG-221 (enasidenib) and mIDH1 inhibitor AG-120 (ivosidenib) have been approved for the treatment of patients with relapsed or refractory AML with a susceptible IDH mutation. Several other compounds, including AG-881, IDH305, BAY1436032, FT-2102 and AGI-6780, are in development. 14 To date, AG-221 and AGI-6780 are the only two inhibitors developed against mIDH2. In particular, both compounds selectively bind to and inhibit the IDH2-R140Q enzyme, but show weak inhibitory effects on IDH2-R172K enzymatic activity. 15, 16 The IDH2-R140Q mutation occurs more frequently than IDH2-R172K in AML, which may be the reason IDH2-R140Q was selected as the primary initial target. However, recent large-scale genomic classification and prognosis studies of AML have suggested that the IDH2-R172K mutation is associated with a unique gene expression and DNA methylation profile that results in more severe aberrations in central metabolism. 14, 17, 18 In a separate retrospective study carried out by the UK Medical Research Council, the CR rate was 88% among R140Q patients and only 48% in those with an R172K mutation, indicating a relatively poor response in IDH2-R172K patients. 19 Thus, developing an inhibitor that targets IDH2-R172K, or ideally one that targets both IDH2-R140Q and IDH2-R172K, would have significant clinical value.
Herein, we rationally designed and synthesized a series of derivatives based on the chemical structure of AG-221. One derivative, TQ05310 (Figure 1 ), stood out in initial screens and was selected for further evaluation. TQ05310 was superior to AG-221 in inhibition of IDH2-R140Q enzymatic activity; more importantly, TQ05310 also potently inhibited IDH2-R172K and had no apparent inhibitory effects on wild-type IDH1/2 enzymes. In this report of major preclinical pharmacological results of TQ05310, we show that TQ05310 is the first mIDH2 inhibitor that potently targets both IDH2-R140Q and IDH2-R172K mutations. 
| MATERIAL S AND ME THODS

| Reagents and antibodies
| Expression plasmids and viruses
Human IDH1 and IDH2 mutants were constructed using standard techniques and subcloned into pLenti-C-Myc-DDK-IRES-Puro or tetracycline-inducible lentiviral pLVX-TRE3G expression vectors.
Primers for site-directed mutagenesis are listed in Data S1. Sequences were verified by Sanger sequencing (Data S1). Lentiviral particles were produced from transiently transfected HEK 293FT cells.
| Cells and lentiviral transfection
HEK 293FT, TF-1, and U-87 MG cells were obtained from ATCC, and cell identities were confirmed by short tandem repeat (STR) DNA profiling analysis in Genesky. HEK 293FT and U-87 MG cells were maintained in DMEM supplemented with 10% FBS. TF-1 cells were maintained in RPMI-1640 medium supplemented with 10% FBS and 2 ng/mL hGM-CSF.
TF-1 cells were infected with tetracycline-inducible pLVX-TRE3G lentiviral particles (IDH2-WT, IDH2-R140Q, IDH2-R172K) to generate TF-1/IDH2-WT, TF-1/IDH2-R140Q, and TF-1/IDH2-R172K cells. 
| Western blotting
Western blot analysis was conducted as previously described. 21 After drug treatment, cells were lysed in SDS sample buffer. Proteins in lysates were separated by SDS-PAGE electrophoresis and then transferred to PVDF membranes. After incubating with primary antibodies and secondary antibodies, proteins were visualized using the Western Blot Imaging System (Clinx Science Instruments, Shanghai, China). 
| Cell-based assays for measuring inhibition of 2-HG production
Cells were treated with TQ05310 or AG-221 for 72 hours. Media were removed and 2-HG was extracted using 80% aqueous methanol and determined by LC-MS/MS.
| Cell-based enzyme assays
Cells were lysed with RIPA buffer (20 mmol/L Tris-HCl, 100 mmol/L NaCl, 1% NP-40, 1 mmol/L EDTA), and cell lysates were centrifuged 
| Cell differentiation
TF-1/IDH2-R140Q and TF-1/IDH2-R172K cells were treated with compounds for 7 days in RPMI-1640 supplemented with 10% FBS and 2 ng/mL hGM-CSF. Erythroid differentiation of cells was induced by replacing GM-CSF with EPO (2 IU/mL) for another 7 days in culture medium containing compounds. After induction, cell pellets were collected for analysis of the expression of HBG.
| RNA isolation and quantitative reverse transcription-polymerase chain reaction
Total RNA was extracted and reverse transcribed as previously described. 22 
| Cell proliferation assay
TF-1/IDH2-R140Q and TF-1/IDH2-R172K cells were treated with compounds for 7 days in medium with 2 ng/mL hGM-CSF, and another 7 days without hGM-CSF. At the end of treatment, MTT solution was added to each well, and plates were incubated for 4 hours at 37°C. Formazan crystals formed were then solubilized in acidic isopropanol, and the optical density of the resulting solution was read at 570 nm using a Synergy H4 microplate reader (BioTek).
| Cellular thermal shift assay
Experiments were carried out using standard techniques. 23, 24 Briefly, after treatment with compounds for 1 hour, cells were harvested and washed with PBS. Cells were then distributed into different tubes (10 6 cells/tube), heated at different temperatures for 3 minutes and lysed using two freeze-thaw cycles with liquid nitrogen.
Soluble fractions were isolated and analyzed by western blotting.
| Molecular docking
The IDH2-R140Q structure from a crystal of the IDH2-R140Q/ AG-221 complex 16 was used as a template. The X-ray crystal structure of this IDH2-R140Q/AG-221 complex (PDB code: 5I96) was obtained from the Protein Data Bank. Molecular docking was carried out using Glide v6.9 in SP mode. LigPrep v3.6 was applied to pre-process the compound using default parameters. The obtained docked poses were analyzed with Maestro, PyMOL, and LigPlot. 25 
| Pharmacokinetic/pharmacodynamic studies
| Statistical analysis
Data were analyzed with GraphPad Prism software. Two-tailed Student's t tests were used to determine the statistical significance of differences between two groups.
| RE SULTS
| Establishment of cell models exogenously expressing mIDH genes
Isocitrate dehydrogenase mutations are heterozygous, and the most common mutational types are IDH1-R132C, IDH1-R132H, IDH2-R140Q and IDH2-R172K. 26 Accordingly, we transfected exogenous mIDH genes (Table 1) into cells endogenously expressing wild-type IDH. Two sets of models were constructed: TF-1 AML cells transfected with inducibly expressed IDH (IDH2-WT, IDH2-R140Q, IDH2-R172K; Figure 2A ), and U-87 MG glioma cells transfected with constitutively expressed IDH (IDH2-WT, IDH2-R140Q, IDH2-R172K, IDH1-WT, IDH1-R132C, IDH1-R132H; Figure 2B ).
Exogenously transfected IDH was expressed at high levels in the respective models, and specific expression of IDH2-R172K was further verified ( Figure 2C and D) . Moreover, exogenous transfection with mIDH enzymes led to significant increases in cellular levels of 2-HG ( Figure 2E ), suggesting elevated IDH enzymatic activity in these cells.
| TQ05310 inhibits mIDH enzymatic activity and 2-HG production in both IDH2-R140Q-and IDH2-R172K-expressing cells
We first evaluated the inhibitory activity of TQ05310 against wildtype and mIDH enzymes using cell-based enzyme assays. As shown in Figure 3A , TQ05310 was more potent than AG-221 in the inhibition of IDH2-R140Q (IC 50 : 136.9 ± 15.8 nmol/L vs 229.3 ± 23.2 nmol/L).
More importantly, TQ05310 was significantly more potent than AG-221 in the inhibition of IDH2-R172K (IC 50 : 37.9 ± 7.3 nmol/L vs 624.5 ± 146.3). Both TQ05310 and AG-221 had no apparent inhibitory effects on IDH2-WT, IDH1-WT, IDH1-R132C or IDH1-R132H enzymatic activity.
We then examined 2-HG levels in cells expressing mIDH2.
Consistent with the inhibitory effects on enzymatic activity, both Figure 3B ). These effects were also confirmed in TF-1 models. Compared with AG-221, TQ05310 showed more potent anti-2-HG activity in TF-1/IDH2-R140Q cells (IC 50 : 9.9 ± 2.8 vs 24.7 ± 2.3) and significantly more potent anti-2-HG activity in TF-1/ IDH2-R172K cells (IC 50 : 40.9 ± 1.6 vs 732.0 ± 331.4) ( Figure 3C ).
Taken together, these data indicate that, unlike AG-221, a selective inhibitor of IDH2-R140Q, TQ05310 is a mIDH2 inhibitor with potent inhibitory effects on both IDH2-R140Q and IDH2-R172K.
| TQ05310 relieves differentiation block in both IDH2-R140Q-and IDH2-R172K-expressing cells
(R)-2-hydroxyglutarate blocks differentiation of hematopoietic progenitor cells, 27 and IDH inhibition has been reported to induce differentiation of mIDH-expressing hematopoietic cells. 16 To examine the effects of TQ05310 on cell differentiation, we measured levels of HBG, a marker of differentiation to erythroid-lineage, in TF-1 AML cells harboring an IDH2 mutation under EPO induction. As shown in Figure 4A 
| Structural basis for the inhibition of IDH2-R140Q and IDH2-R172K by TQ05310
To determine whether TQ05310 inhibited mIDH2 by directly binding to mIDH2 protein, we then carried out CETSA, a method for evaluating drug-target interactions. 28 As shown in Figure 5A , TQ05310 exerted strong thermal-stabilizing effects on both IDH2-R140Q and IDH2-R172K, indicating binding of TQ05310 to both proteins; AG-221 had an apparent thermal-stabilization effect on IDH2-R140Q (weaker than TQ05310) and a weak thermal-stabilization effect on IDH2-R172K, indicating preferential binding of AG-221 to IDH2-R140Q. Neither TQ05310 nor AG-221 stabilized wild-type IDH2.
Next, we further explored the binding sites of TQ05310 by structural modeling using the IDH2-R140Q structure from a crystal of the IDH2-R140Q/AG-221 complex 16 as a template. TQ05310 was found to occupy the same active pocket of IDH2-R140Q as AG-221 ( Figure 5B ). Modeling showed that nitrogen on the diaminotriazine core accepts hydrogen bonds from the amino side chain of the Q316 residue, and linker nitrogens donate hydrogen bonds to the Q316 carbonyl side chain ( Figure 5B ). Thus, Q316 is the critical residue that mediates binding of TQ05310 with IDH2-R140Q. Because there is no reported crystal structure of IDH2-R172K in complex with inhibitor, we did not conduct structural modeling of TQ05310 using this mutant. To confirm the critical role of the Q316 residue, we carried out site-directed mutagenesis (predicted with SIFT: https :// sift.bii.a-star.edu.sg/) to construct plasmids for IDH2-R140Q-Q316A, IDH2-R140Q-Q316I, IDH2-R172K-Q316A and IDH2-R172K-Q316I, and transfected these plasmids into U-87 MG glioma cells. Exogenous expression of IDH2-R140Q-Q316A or IDH2-R172K-Q316A led to significant increases in cellular levels of 2-HG. In contrast, IDH2-R140Q-Q316I and IDH2-R172K-Q316I had no such effect, indicating that the Q316A mutant, but not the Q316I mutant, retained its activity ( Figure 5C ). We then carried out CETSA in cells transfected with IDH2-R140Q-Q316A or IDH2-R172K-Q316A. As shown in Figure 5D , the thermal-stabilizing effects of both TQ05310 and AG-221 were lost in U-87 MG/IDH2-R140Q-Q316A cells, confirming the critical role of the Q316 residue in binding of these two inhibitors with IDH2-R140Q.
However, TQ 05310 retained its thermal-stabilizing effects in U-87 MG/IDH2-R172K-Q316A cells, suggesting that the Q316 residue is not the only critical residue in the binding of TQ05310 with IDH2-R172K.
| Pharmacodynamic and pharmacokinetic characterization of TQ05310
Given the superior activity of TQ05310 against mIDH2 in vitro, we next analyzed its pharmacodynamic and pharmacokinetic pro- Figure 6B ).
Collectively, these results suggest that TQ05310 has favorable pharmacokinetic characteristics and can inhibit 2-HG production in vivo.
| D ISCUSS I ON
Mutant IDH2 enzymes, which lead to various metabolic alterations, are extensively expressed in AML and glioma patients.
However, despite their shared 2-HG production, IDH2 mutations are not alike and differ in tumorigenic properties. 29 AG-221, an mIDH2 inhibitor, has been approved for the treatment of patients with relapsed or refractory AML harboring an IDH2 mutation.
However, despite its strong inhibition of IDH2-R140Q, AG-221 has very weak inhibitory activity against IDH2-R172K. Here, we identified TQ05310 as a novel mIDH2 inhibitor that targets both IDH2-R140Q and IDH2-R172K mutants.
TQ05310 is a novel, potent, and orally available inhibitor of IDH2 that is superior to AG-221, the most successful IDH2 inhibitor developed to date, in several respects.
First, TQ05310 was significantly more potent than AG-221 at inhibiting IDH2-R172K-mediated processes. The structure of IDH2-R172K is very different to that of IDH2-R140Q. 30 All mIDH2 inhibitors have been designed to target IDH2-R140Q, and show very weak inhibitory effects on IDH2-R172K. 15, 16 Unlike these inhibitors, TQ05310 very strongly inhibited IDH2-R172K, significantly inhibiting enzymatic activity and 2-HG production, and inducing differentiation in cells transfected with IDH2-R172K. CETSA confirmed that TQ05310 directly binds to IDH2-R172K. TQ05310 was superior to AG-221 in all of these aspects, suggesting that TQ05310 would have an enormous advantage in the treatment of patients with IDH2-R172K.
Second, TQ05310 showed potent inhibitory effects against IDH2-R140Q-mediated processes. TQ05310 was even more effective than AG-221 in inhibiting IDH2-R140Q enzymatic activity and 2-HG production, as well as in inducing differentiation of cells transfected with IDH2-R140Q. Taken together, these results provide a basis for the application of TQ05310 in the treatment of patients with IDH2-R140Q.
In addition to its remarkable in vitro characteristics, TQ05310 also had favorable pharmacokinetic and drug-like properties. In the U-87 MG/IDH2-R140Q xenograft model, TQ05310 was rapidly absorbed and showed much higher accumulation in tumors than in plasma. Moreover, TQ05310 rapidly reduced 2-HG to a low level in tumors and sustained it for at least 24 hours post-dosage.
To explore the binding mode of TQ05310, we constructed different models with IDH2-Q316 mutations. We found that the thermal-stabilizing effects of TQ05310 and AG-221 were lost in U-87 MG/IDH2-R140Q-Q316A cells, suggesting the critical role of the Q316 residue in binding these two inhibitors with IDH2-R140Q, and that the Q316 mutation may cause resistance to these inhibitors in patients with IDH2-R140Q. Notably, a study based on clinical observation reported that an AML patient with IDH2-R140Q showed an initial clinical response to AG-221, but developed drug resistance and disease progression after the emergence of the Q316E mutation in IDH2, 31 which confirmed the critical role of the Q316 residue in drug sensitivity. Collectively, these results indicate that monitoring Q316 mutations is important to predict the effectiveness of AG-221 and TQ05310 in patients harboring the IDH2-R140Q mutation.
Taken together, the findings of the present study show that TQ05310, the first mIDH2 inhibitor having strong inhibitory effects on both IDH2-R140Q and IDH2-R172K, has superior activity compared with AG-221 in preclinical models, supporting its further clinical investigation for patients harboring IDH2-R140Q or IDH2-R172K mutations. F I G U R E 6 Pharmacokinetic/ pharmacodynamic characteristics of TQ05310. Mice bearing U-87 MG/IDH2-140Q xenografts were given a single oral dose of TQ05310 (18.05 or 54.14 mg/kg) and were killed at the indicated times. Concentrations of (A) TQ05310 and (B) (R)-2-hydroxyglutarate (2-HG) production in plasma and tumor were determined
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